Journal News

Starved for oxygen, T cells flag in cancer fight

Laurel Oldach
Sept. 6, 2022

Cytotoxic T cells exist to kill cells subverted by infection or mutation. That makes them the focus of a lot of immuno-oncology research. Although cancers must slip past immune recognition to become established in the first place, immunotherapies such as checkpoint inhibitor antibodies or T cells with modified receptors can retrain the immune system to focus on cancer cells.

So far, this has worked best for blood cancers with many cells spread throughout the body. Solid tumors have been harder to treat. The inside of a tumor differs from normal tissue in complex ways that add up to make it a very immunosuppressive environment.

In a preliminary study published in Molecular & Cellular Proteomics, postdoc James Byrnes and colleagues in Jim Wells’ lab at the University of California, San Francisco, report on their research into how the proteins on the surface of a cytotoxic T cell respond to various stimuli they might encounter in a tumor.

Using primary cells removed from human blood, the team focused on the surface proteome of cytotoxic CD8+ T cells. They investigated how interactions with T regulatory cells, which dampen T cells’ response and help end an immune reaction, and oxygen limitation, a feature of many tumors, changed the cytotoxic T cell surface.

A group of killer T cells (green and red) surround a cancer cell (blue, center). When a killer T cell makes contact with a target cell, the killer cell attaches and spreads over the target, then uses special chemicals housed in vesicles (red) to deliver the killing blow. The killer T cells then move on to find the next target.
National Institutes of Health
A group of killer T cells (green and red) surround a cancer cell (blue, center). When a killer T cell makes contact
with a target cell, the killer cell attaches and spreads over the target, then uses special chemicals housed
in vesicles(red) to deliver the killing blow. The killer T cells then move on to find the next target.

T regulatory cells are abundant in some solid tumors, and the team expected them to have dramatic effects. They were surprised to find that hypoxia had a much greater effect.

“The prevailing thought is that T regulatory cells are this super-potent immunosuppressive factor,” Byrnes said. But growing CD8+ T cells with T regulatory cells changed only a targeted subset of proteins, mostly the ones that increase in abundance after activation and are involved in signaling and proliferation.

“The T-regs are reversing the activation phenotype,” Byrnes said. “Hypoxia is a little more of a sledgehammer.”

Oxygen starvation shifted cytotoxic T cell expression of many surface proteins: The cells reduced immune signaling receptors and increased metabolic proteins, apparently in an effort to survive using glycolysis. Other studies have shown that hypoxia can make T cells more prone to kill but also slower to multiply; on balance, they may become less effective.

The Wells lab is focused primarily on antibody engineering, Byrnes said, and these results have given them interesting leads to follow as they consider new ways to mobilize the immune cells within a tumor. “We’re hoping … (to) gain biological insight into what some of these proteins are doing, as well as identify handles that we can use to therapeutically engage hypoxic T cells.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Laurel Oldach

Laurel Oldach is a former science writer for the ASBMB.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Light-activated small molecule could transform eye infection treatment
News

Light-activated small molecule could transform eye infection treatment

April 21, 2026

Contact lenses raise the risk of infectious keratitis, a leading cause of blindness worldwide. A biotech company is commercializing a light-activated therapy using a ROS-generating molecule to rapidly kill microbes in the cornea to preserve vision.

The molecular orchestra of memory
Feature

The molecular orchestra of memory

April 16, 2026

Calcium, calmodulin and calcium/calmodulin-dependent kinase II form a molecular axis that turns fleeting neural activity into lasting memories. New research shows how memories are stabilized, and possibly even protected or repaired.

Differences in pili structure modulate bacterial behavior
Journal News

Differences in pili structure modulate bacterial behavior

April 14, 2026

Researchers demonstrate how small changes in the structure of hair-like protein appendages can affect the behavior of Acinetobacter bacteria.

Cholesterol regulatory genes predict liver transplant outcomes
Journal News

Cholesterol regulatory genes predict liver transplant outcomes

April 10, 2026

Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.

Lipid signatures for a rare neurological disorder
Journal News

Lipid signatures for a rare neurological disorder

April 10, 2026

Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.

Disease-linked mutations disrupt protein phase behavior
Journal News

Disease-linked mutations disrupt protein phase behavior

April 9, 2026

Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.